Merck & Co., Inc. $MRK Stock: Investment House LLC Reduces Position

Key Points

• Investment House LLC cut its Merck stake by 47% in the third quarter, selling 25,843 shares and retaining 29,177 shares worth approximately $4.24 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Analyst sentiment remains broadly positive: 17 analysts rate Merck a Buy, nine a Hold and one a Sell, producing a consensus “Moderate Buy” rating and a $151.92 price target.
• Merck reported quarterly revenue of $16.61 billion, above expectations, and maintained a quarterly dividend of $0.85 per share, equivalent to a 2.3% yield. However, insider selling totaled roughly $30 million over the last quarter, while upcoming earnings and moderating KEYTRUDA growth remain concerns.

Investment House LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 47.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,177 shares of the company's stock after selling 25,843 shares during the quarter. Investment House LLC's holdings in Merck & Co., Inc. were worth $4,240,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Horizons Wealth Management purchased a new position in Merck & Co., Inc. during the third quarter worth approximately $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. in the second quarter valued at approximately $27,000. Graney & King LLC increased its position in shares of Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after buying an additional 200 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $41,000. Finally, Evergreen Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the 1st quarter worth approximately $43,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MRK. TD Cowen lifted their price target on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a research note on Wednesday, September 23rd. Leerink Partners increased their price objective on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a research report on Friday, September 4th. Cantor Fitzgerald boosted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a "neutral" rating in a research note on Thursday, October 8th. Finally, Morgan Stanley decreased their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 7th. Seventeen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $151.92.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last quarter. Corporate insiders own 0.17% of the company's stock.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $147.40 on Friday. The company has a market cap of $363.67 billion, a P/E ratio of 117.92, a P/E/G ratio of 6.92 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The company's 50-day moving average price is $146.79 and its 200-day moving average price is $130.07.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported Phase 3 INTerpath-001 results showing that intismeran autogene combined with KEYTRUDA reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. The data met market expectations and could support a future expansion of Merck’s oncology pipeline beyond KEYTRUDA. Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
• Positive Sentiment: The European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. The wider label expands the addressable market for Merck’s leading oncology franchise and may help offset future pressure from slowing KEYTRUDA growth. European Commission approves KEYTRUDA plus Padcev
• Neutral Sentiment: Trading activity included approximately 37,444 MRK call options, about 40% above average daily volume, indicating increased speculative interest but not establishing a clear direction for the shares.
• Negative Sentiment: An apparent early leak of the melanoma-vaccine data caused volatility and appears to have prompted profit-taking. Investors may have expected a larger-than-reported benefit despite the statistically and clinically positive results, creating a sell-the-news response ahead of the formal ESMO presentation. Moderna, Merck shares fall after possible melanoma data leak
• Negative Sentiment: Analysts expect Merck’s upcoming third-quarter earnings to decline, limiting near-term enthusiasm and reinforcing concerns about moderating KEYTRUDA growth. Zacks also reportedly downgraded MRK from “hold” to “strong sell,” adding pressure to sentiment.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.